Careers Contact
Careers Contact

AI platform

AI-Immunology™ harnesses the power of artificial intelligence to decode the human immune system and develop novel drug candidates for cancer and infectious diseases.

The power of AI-Immunology™ in target discovery, drug design and development

A pioneering platform, AI-Immunology™ stands out from other AI-based technologies in several ways.  

In development of cancer vaccines, AI Immunology™ has demonstrated an 86% target hit-rate, meaning that 86% of the vaccine targets identified by the platform trigger a tumor-specific immune response. This rate is much higher than what has been reported for other methods. Further, there is a significant correlation between the platform’s predictions and the immune responses measured in patients, demonstrating very strong predictive capabilities. 

In development of prophylactic vaccines for infectious diseases, AI Immunology™ has also demonstrated unique predictive power as well as the ability to identify novel B-cell antigens. Further, it can combine B-cell antigens and T-cell epitopes in simple functional antigen constructs, optimize design of known antigens and provide solutions for hard-to-produce antigens. 

On top of these disease specific features, AI-Immunology™ is also unique in having an integrated design module meaning the platform provides not only targets but complete, optimized suggestions for concrete vaccine designs. 

0

clinical trials confirm predictive capabilities and link to outcomes

0HRS

to complete target discovery

0%

fewer targets needs testing

0%+

on average cheaper target discovery versus reverse vaccinology

0%

vaccine target hit-rate

0

different modalities (protein, DNA, mRNA, peptides)

0+

different diseases can be addressed

Decoding the human immune system with AI

AI-Immunology™ combines deep biological insight with advanced artificial intelligence to discover new relevant targets (approaches to treatment of diseases) that cannot be determined by traditional methods. This includes both personalized and off-the-shelf therapeutic cancer vaccines as well as prophylactic vaccines for infectious diseases. 

The platform’s validated predictive capabilities allow for fast and effective antigen discovery, drug design and development. As such, AI-Immunology™ is a platform for development of novel treatments that could potentially address significant unmet medical needs. 

AI-Immunology™, which has been continuously refined and improved through almost two decades, is currently being applied within several cancers and infectious diseases but is scalable to more than 100 different diseases. These include autoimmune diseases, which we will add as a new disease focus area later in 2026. 

Built on decades of protection and immunological data

Since 2008, AI-Immunology™ has been trained and fine-tuned on decades of protection and immunogenicity data from public databases and proprietary datasets curated by in-house experts. This continuous refinement allows the platform to rapidly and accurately identify effective targets for vaccines against cancer and infectious diseases. 

Vaccine targets include T-cell epitopes from cancer and pathogens as well as B-cell antigens. Examples include cancer neoantigens, cancer-specific dark proteome fragments (including endogenous retroviruses, ERVs), and epitope-rich proteome fragments of pathogens. 

Using an unbiased discovery approach, the platform identifies novel drug targets that traditional methods often overlook. This expands the pool of targets and enables the discovery of transformative candidates that might otherwise remain undetected.